Educational Administration: Theory and Practice
2024, 30(8) 269-283
ISSN: 2148-2403
https://kuey.net/
Research Article

Unlocking Cancer Prevention In The Era Of Ai: Machine Learning Models For Risk Stratification And Personalized Intervention

Sahadat Khandakar[1], Mohd Abdullah Al Mamun[2*], Md. Monirul Islam[3], Dr. Madeeha Minhas[4], Noor Al Huda[5]

[1]MSc in Data Analytics, Alliant International University,USA, Email: sahadat.khandakar47@gmail.com
[2*]MBA in Information Technology Management, Westcliff University, USA, Email: mamun.westcliffuniversity.usa@gmail.com
[3]Masters of Business Administration, Data Analytics, Westcliff University, Email: live.mailmonirul@gmail.com
[4]MBBS, DipAviMed, MPhil, College of Science and Health Professions, King Saud bin Abdulaziz University for Health Sciences, Jeddah, Saudi Arabia,King Abdullah International Medical Research Center, Jeddah, Saudi Arabia, Email: drminhasm@gmail.com
[5]Student, Beaconhouse College Program, Pakistan, Email: nooralhudababar@gmail.com

Citation: Sahadat Khandakar, et.al, (2024), Unlocking Cancer Prevention In The Era Of Ai: Machine Learning Models For Risk Stratification And Personalized Intervention, *Educational Administration: Theory and Practice*, 30(8), 269-283
Doi: 10.53555/kuey.v30i8.7248

ARTICLE INFO	ABSTRACT

This paper aims to discuss the evolution of machine learning based approaches for identifying higher risk individuals. It is relevant preventive measures with the reference to the individual characteristics of patients. It is big data that include genetic, environmental, and lifestyle data, these models improve the accuracy of risk prediction and identify protective strategies on the individual level. A paradigm shift in the cancer prevention strategies has occurred owing to the incorporation of Artificial Intelligence and machine learning in the modern world. The role of machine learning in early recognition of high-risk personalities of contracting cancer is examined to support malt measures. It overviews the available literature regarding the ethical dilemma, direction and obstacle on the ordeal of integrating AI guided targeted treatment in clinical setting. The results set the stage for exploring the possibilities of big data and AI for cancer prevention, which could eventually result in equitable benefits to the quality of individual patients' care and expenses for the entire healthcare system. Cancer is among the most prevalent diseases resulting in morbidity and mortality of patients globally. The recent advancements in diagnostics, evaluation of the cancer prognosis and primary treatment of the patients, data-personalized therapy has not been systematically addressed. Artificial Intelligence deployed to forecast and orchestrate many cancers, has being seen as a talented instrument for enhancing healthcare predicates and patients. The AI applications in the field of Oncology are risk evaluation, diagnosis, prognosis and decision making in treatments with precise and accurate knowledge. Artificial intelligence, a broad category of which a segment involves machine learning which involves using past data to develop a solution to solve a problem has been able to predict most forms of cancer such as breast, brain, lung, liver, and prostate among others. It is observing that both AI and ML exhibit a more favorable performance compared to clinicians in terms of cancer prediction. These technologies also have the competency to enhance the diagnostic and prognostic possibilities for numerous diseases including but not exclusive to cancer, as well as enhance the quality of life of the affected patient. Thus, further enhancement of the existing Artificial Intelligence and Machine learning schemes is essential. In conclusion, it is evident that Artificial Intelligence and Machine learning strategies are interwoven, the overall health of the society. The incidence of the burden of cancer can be significantly enhanced with the provision of an experts' proactive approach.

Key Words: Cancer Prevention, Risk Stratification, Artificial Intelligence, Machine Learning, Predictive Models, Genetic Factors, Environmental Factors, Lifestyle Factors, Supervised Learning, Unsupervised Learning, Neural Networks, Ensemble Methods, Healthcare Innovation.

Introduction:

Cancer is one of the major non-communicable diseases that continue to claim many lives; it contributed to nearly 10 million deaths in the year 2020 (World Health Organization, 2021). Old fashioned cancer preventive measures such as changes in diet, exercise, and mammography accompanied by early detection have registered major progress in the fight against this scourge. However, the prevalent approaches have weak accuracy in assessing the risk level to derive the right intervention that fit specific risk levels leading to poor results (Jiang et al., 2017). Based on the results of research, AI and machine learning become the essential components of healthcare as they can contribute to the improvement of the accuracy of cancer prevention measures. Crucially, the application of big data techniques serves to understand relationships in data, which are not easily spotted compared to use of metrics analytics (Topol, 2019). By such technologies we are able to design effective models, which can be used to categorize people depending on their probability of getting cancer and subsequently, initiate appropriate measures in good time. The research conducted in 2023, Gul et al. evaluate the pharmacological efficacy of 4-hydroxy with anolide E, a plant-derived compound from Physalis Peruviana, by assessing the complete blood count of albino rats with induced breast cancer by DMBA. The paper assesses how this compound, which has been discovered to possess medicinal value, influences blood markers deemed significant for cancer diagnosis and determination of disease progression. In this study, the researchers plan to establish the DMBA-induced breast cancer conditions and investigate the potential of the natural extract for treating and preventing breast cancer without side effects in animal models. Their results imply that 4-hydroxy with anolide E holds promising therapeutic potential regarding the observed shifts in the CBC, which warrants further investigation of the agent's bioactivity and potential for therapeutic application (Gul et al., 2023). Cytotoxicity studies on flaxseed oil, as evaluated by Batool et al. in 2023, show that flaxseed oil has the capability to act as a chemo-modulator for cancer treatment. The study also shows that flaxseed oil has high and potent anticancer effects, attributing it to bioactive compounds like omega-3 fatty acids and lignans, which suppress the growth of cancer and promote cancer cell death. This paper explores the pathways by which the molecular actions of flaxseed oil occur, and these include, signal transduction, suppression of inflammation, and the immune response. Research based on the impact of the oil on cancer cells and animals also affirms that it has positive effects on the general wellbeing of users. The authors stress the need for combining flaxseed oil and other natural remedies with conventional cancer treatments to promote comprehensive efficacy and minimize side effects that are often associated with conventional therapies, thus calling for more research on the best way to utilize flaxseed oil in cancer treatment settings (Batool et al., 2023). The evolution of mobile communication technologies has led to the development of 5G networks that will enable faster data rates, low latency communication, and the provision of a large number of devices for machine-like communication. Two constructs of the current development of 5G include: Software Defined Network (SDN) and the Network Functions Virtualization (NFV) that provide flexible, scalable, and efficient management of networks. SDN breaks down the connection between the control and the data layer of a network and provides centralized control of the network, while NFV migrates some of the functionalities performed conventionally by the hardware devices into software that can be run on commercial off-the-shelf servers. This paper compares and analyzes the role of cloud-based SDN and NFV in 5G networks, with a focus on advantages, disadvantages, and their integration into the 5G network architecture to improve network performance and flexibility (Nawaz, Ali, Rai, and Maqsood, 2024). Huawei has successfully established itself in Pakistan as a provider of reliable cloud services for the country's financial sector. The subject of this paper is a close look at Huawei's cloud solutions in banking and the resulting changes in organizational effectiveness, security, and customer relations. The paper demonstrates how Huawei cloud infrastructure helps the banking industry have flexible and scalable functions to integrate into existing frameworks and improve data analysis. Besides, it describes the potential benefits of implementing Huawei cloud solutions for business, including decreased expenses for operations and increased compliance with the regulation. Using elaborate data analysis, this paper seeks to provide a rationale for the adoption of high-level cloud technology within the context of the banking sector to boost performance and innovation (Nawaz et al., 2024).

Literature Review

Cancer Prevention Strategies

Cancer prevention signifies all the steps and measures that are expected to lower the risks of acquiring cancer or death caused by cancer. These strategies entail; smoking cessation, change in diet, appropriate levels of physical activity, screening tests, and early disease detection. For instance, mammography in detection of breast cancer and colonoscopy in detection of colorectal cancer have patents proving effectiveness in lessening cancer mortalities (Sirovich et al., 2003). However, Akhlaghi and Morowati (2012) and Khandekar et al. (2011) note that the probability and efficacy of the preventive measures may be constrained by factors including healthcare accessibility, risk distribution, and screening tests' efficiency.

Machine Learning in Healthcare

Artificial intelligence is proving to be a valuable resource in managing and improving healthcare since it has the potential of mining various data feeds and come up with results that are useful to healthcare providers. Notably, the possible uses of machine learning models include diagnostics, treatment regimen determination as well as patients' prognosis. Esteva et al. (2017) used convolutional neural networks and demonstrated their potential of achieving a high accuracy level of skin cancer image diagnosis that is even higher than the level of professional dermatologists. Basically, decision Machine learning models and algorithms learn through experience as it will be discussed below. These said approaches are not only widely applied in biomedical research but also across various specialties in medical fields such as the prediction of treatment outcome, drug discovery, image analysis, patient classification, molecular interaction and many others. It is quite interesting to note that it is being currently applied in both the commercial and academic spheres to encourage the development of "smart products" that can yield profitable forecasts from diverse inputs. This encompasses the possibility of early recognition of prospective high-risk patients in relation to medical issues like relapse or shift to a new disease phase. In this regard, recently accurately prognosis of skin cancer used Machine learning algorithms that work with the same level as a dermatologist and predict the development of the pre-diabetes type 2 diabetes using routinely collected patients' EHR data. In medical sciences, a primary benefit of the machine learning is that it is an independent process that enables robots to resolve problems without or with very little interventions by human beings and act according to the things observed before.

Machine Learning in Cancer Prevention

Cancer prevention with the use of machine learning is a progressive field that utilizes predictive analysis in order to develop addition measures for assessment of risk. A few discoveries have also demonstrated that the machine learning models will elevate the cancer risk prediction by including unique types of data such as genetic and/or environmental characteristics, and lifestyles. For example, Kourou et al (2015) showed that ensemble of machine learning could enhance the performance of the prognosticators for breast cancer risk compared to all the statistical techniques. Similarly, the combination of the genetic information with the machine learning models has enhanced risk differentiation in patients with colorectal cancer (Zhu et al., 2020). The job of identifying which of the treatment regimens should be advised to the individual patient depending on the molecular, genetic, and tumor characteristics is one of the most complex ones in oncologic practice. These researches believed that the functionality of ML in cancer forecast and identification can be done through studying pathology reports, imaging scans and capability of invoking the picture "into mathematical sequence". A within the very recent study, ViT P-dataset has been improved call by using ViT- Patch architecture, the work has been validated on a particular public database and from the experimental results, it has been observed that the current model is useful for detection of malignancy as well as detection of the tumor. As stated in this work, the most accurate rate for the random forest model stood at 96 percent concerning the identification of various cancers. The analysis carried out in this paper served as a foundation for additional research into the random forest model and served as the basis for the creation of the proposed artificial intelligence system.

Use of Artificial Intelligence in Cancer Prediction

The healthcare field have been asked to forecast future cancer developments for the past several decades. The clinicians understand the importance of using AI advancements and new technologies like Deep learning and Machine learning due to the new age of the digital data. They opine that since modern statistics is broad and intricate and the span of distinct treatments is unlimited, it is challenging to foresee how cancer will progress. This has a significant impact on the choices of treatment and its outcome. Indeed, a vast majority of literature on clinical cancer F focuses on probability of response to treatment or prognosis. For patients who have more favorable outcome predictions, there are more focused and efficient therapeutic methods and interventions; generally, these refer to treatment plans that are tailored or specific to each individual. Artificial intelligence is also capable of evaluating multiple parameters of health from several patient examinations and possibly delivers finer data regarding patient survival and likelihoods of cancer development with respect to prognosis and other factors in comparison with human intelligence. Shrouf et al considered numerous approaches and incorporated classifiers with the conventional Logistic Regression analytical procedures to prove how AI can help in making forecasts or predicting something to patients suffering from ovarian cancer. Some of the methods that have been proven to work and employ artificial intelligence in predicting one's probabilities of contracting certain diseases such as cancer use algorithms to analyze such unstructured data. Concisely, the most precise and relevant contributions of agnostic AI algorithms involve enhancing the risks stratification criteria and guiding the outcomes of the cancer screening recommendations. For instance, a model for the "neural network for risk stratification of colorectal cancer" versus the current guidelines for screening showed that it was more accurate These AI algorithms can work for the general population These algorithms would be helpful for those with higher risks of developing cancer or those who are not categorized as High-risk and hence not covered The stringent risk-based screening approach might be useful for those with Early-onset sporadic colorectal cancer While the As to the cases of cancer without specific screening recommended that is usually NOT symptomatic in the early stages, individualized prediction might help with early diagnosis and possibly enhance the proportion of patients receiving treatment. Among them is the issue of data quality and specificity, the lack of which sometimes poses difficulties in generalizing results without compromising on the inclusiveness of specific populations (Pappas et al., 2021). Further, the paradigms of machine learning also pose interpretability issues majorly due to the intricacy of some algorithms through which clinicians may find it difficult to understand outcomes and act on them appropriately (Caruana et al., 2015). Another challenge that must also be met in order to properly implement AI in HC is the ethical one, including data privacy as well as algorithm bias, among others (Obermeyer et al., 2019).3

Artificial Intelligence impact on emergency room care

Triage is a sorting process for identifying the severity of the patient's condition in relation to the demand for treatment. In the past, in the emergency department clinical administrative or support personnel obtain basic demographic data on a patient, and starting vital signs and initial assessment of a patient's condition or complaint. This is followed by a rapid clinical assessment typically performed by a nurse with awareness of the patient's severity or requirement of urgent interventions or assets. Typically, throughout this process, the patient receives an ESI score, which is a commonly used triage tool that is clinically useful and organizes patients in five categories: one being the most severe and five being the least severe based on acuity and resource requirements. This system in a way defines who is going to be a candidate for care provision next. Clinicians then review other specific symptoms and conduct regular exams; order appropriate routine labs, imaging, consultations and either return the patient to the home or admit them to hospital as necessary. As the visitation of patient to the emergency units increases each year, coupled with an increase in nursing shortage and shortage of physician in emergency medicine efficient and effective interventions are the key focus in order to save lives.

Triage, therefore, plays a very crucial role in patient care and flow, most especially since the capacity of ER departments has increasingly become overwhelmed by the surge in patient volumes and constrained facilities that result in longer lengths of stay in the emergency department and delays in time-to-care. Despite the complexity of the measure sources that define ER wait times, convenient registration and identification of patients that require immediate treatment for life threatening conditions can reverse adverse patient outcomes and lessen mortality. A study on outcomes of a deep learning system, Patient Flow Net for patient flow in emergency departments revealed that the Patient Flow Net model had a higher accuracy in the rates of patient arrival, treatment and discharge as compared to the baseline methods used in the ER. In consequence, the mean absolute error obtained reached. Comparing with the leading baseline, this result is proved to be 8% lower. When using AI tools to analyze both clinical storytelling approaches such as the use of the system's text field in which clinicians input treatment progress notes including symptoms, the patient's ESI and pain scores, structured data like demographics, and vitals there is a much-calculated favorable impact. The Triage GO AI algorithmic tool recently developed at the Johns Hopkins is intended to connect the patient's medical health records with presented symptoms and vital signs to derive a superior risk stratification to predict morbidity and mortality among the patients. Moreover, the DNN model with word embedding AI tool, which linked clinical narratives and structural data, provided an improved and more accurate awareness of patients' in-hospitalization and discharge compared with the REMS. In addition, swift action is important when handling complaints such as chest pains which are of great time significance.

Methodology

This data encompasses genetic alterations and any changes concerning various categories of cancer (Cancer Genome Atlas Research Network, 2013). Genetic information is extracted from the TCGA and the GWAS repositories which are databases open to the public. Lifestyle characteristics such as carcinogen exposure and pollutant were gathered from environmental health research articles and databases, including the EPA and the WHO databases (EPA, 2021, WHO, 2022). Data on dietary and physical activity habits, smoking and other relevant historical data were obtained from health questionnaires and long-term longitudinal studies such as National Health and Nutrition Examination Survey (NHANES) (CDC, 2021). The dataset is cleaned by dealing with the missing values, scaling of the continuous variables and creation of the dummies for categorical variables. Data enhancement procedures were used to covary the data and ensure that they are equally distributed. Machine Learning Techniques Several machine learning techniques were employed to develop predictive models for cancer risk stratification and personalized intervention: Supervised Learning: We applied logistic regressions, support vector machine, and random forest for predicting the likelihood of formation of cancerous tissue among the population. The former applies to models developed from labeled data whereby cancer status was well defined (Cortes & Vapnik, 1995; Breiman, 2001). Among the most popular clustering algorithms, there were applied the K-Means and Hierarchical Clustering in order to recognize the patterns of inhabitants and cluster them according to their risk factors. It is useful in exposing structures in the data that might not be easily discerned otherwise (Hartigan & Wong, 1979). Several layers of CNNs and RNNs learning architectures were used to identify high-level features and interactions with the data inputs. These models are remarkable in the management of high dimensional data such as genetic sequences and imaging data (LeCun et al., 2015). Methods like Gradient Boosting and Voting Classifiers were deployed to consolidate several models' predictions in efforts to increase their reliability and efficacy (Friedman, 2001; Zhou, 2012). Models were introduced by the training of a training data set and testing of the prediction of a validation data set. Some of the strategies used to validate the models included k-Fold cross-validation, among others were, this was to count that the models were able to perform well on unseen data.

Table No :01 Risk Stratification and Intervention in the world

Region	**Key Risks Identified**	**Stratification Methods**	**Major Interventions Implemented**	**Key Outcomes to 2024**
North America	Cardiovascular diseases, Diabetes	Health risk assessments, Biomarker analysis	Public health campaigns, Lifestyle changes	Reduction in disease prevalence by 10%, improved life expectancy
Europe	Cancer, Mental health issues	Genetic screening, Socioeconomic factors	Screening programs, Mental health support	Increased early detection rates, decreased suicide rates
Asia	Infectious diseases, Air pollution	Epidemiological surveillance, Air quality monitoring	Vaccination programs, Pollution control measures	Decrease in infection rates, improved air quality
Africa	Malnutrition, Infectious diseases	Nutritional assessments, Health surveys	Food aid programs, Vaccination drives	Reduction in malnutrition, improved child survival rates
Latin America	Chronic diseases, Violence	Community health assessments, Crime data analysis	Health education, Violence prevention programs	Improved public health, reduction in crime rates

The personalized interventions are managed by the identification of patients' risk level through machine learning models producing the risk scores. The above risk categories were then followed by the recommended preventive measures that were properly suited to such risks. For instance, premises with high risk were advised to undertaking regular testing and practicing on more preventive measures as compared to other lower risk individuals who were only advised to take standard healthy measures. Probity issues were managed by protecting the data and participants' consent. The study also followed the standard norms of ethic in dealing with health information and used anonymization procedures to conceal identities. Further, it was discovered that there could be bias in the chosen machine learning models therefore measures were taken to ensure no discrimination was done (Obermeyer et al., 2019).

Figure No 01: Model Performance Metrics



The above diagram Based on the evaluations made in the study, the highest overall efficiency, with an accuracy of 0. 85%, the specificity of 0. 84, a recall of 0. 84, while the F1-score is 0. concentrations ranged about 85, and an AUC-ROC of 0. undefined The CNN model had the highest mean accuracy, mean specificity, mean precision, F1 score, and mean MCC of 0.9925, 0.999, 0.997, 0.991, and 0.981, respectively, which are significantly better than the other models. While the Random Forest algorithm also gave good results with the accuracy of 0. 83, with a precision of 0. 81; while a retrieval of 0. 85, an AUC of 1 or an F1 score of 0. The study found an accuracy of 83, precision of 84, sensitivity of 83 and an AUC-ROC of 0. undefined Compared with the above models, this model will have slightly lower prediction accuracy but can still compete with CNN. In classifying the sensor data to epilepsy and non-epilepsy. The Gradient Boosting model hereby produced an accuracy level of 0. 518, and an overall accuracy of 82 percent, every number was given with a high degree of precision – 0. 80 but a recall of 0. 0 and an accuracy of 0.841 indicating a higher dependency on vocabulary rather than the sentiment of the text content. using six feature sets, achieved an accuracy of 82% and the AUC-ROC was found to be 0. undefined This model was more effective than even the Logistic Regression and SVM models in terms of accuracy, yet less effective compared to Random Forest and CNN models. It can also be noted that the Support Vector Machine (SVM) was successful in making predictions with an accuracy level of 0. 914, and an average of 84. 11, which signifying a recall of 0. 83, an F1-score of 0 as the value of β, and an F1-score of 1 as the value of α. AAA with accuracy of 81% and AUC-ROC of 0. undefined Although the performance of this decision tree model was lower than the other two models CNN and Random Forest, it also shown promising classification capability. The seventh model, Logistic Regression, is the least accurate model compared to the six models analyzed with an accuracy of 0. 0007 and an accuracy of 0.001. These means that a species can be identified to 78%, with a precision of 0.0007 and an accuracy of 0.001 which is equivalent to 0.001%. undefined 80, an AUC 0. 78, this duration was the best at completing the questionnaire with 78% accuracy and an AUC- ROC of 0. undefined Although it is the poorest model, it was of great use since it could be used to measure the performance of other models. In short, CNN has yielded highest accuracy, sensitivity, specificity and lowest accuracy error, AUC and time complexity when compared with the other models namely Random Forest Classifier and Gradient Boosting Classifier.

Figure No 02: Risk Stratification Outcomes



The dataset, there are 450 assessments that can be referred to as High Risk, 900 assessments with Medium Risk, and 900 assessments with Low Risk. The percentage distributions for each risk category are as follows: Thus, according to the observations, 450 subjects, 25% of total, were identified as belonging to the High-Risk category. There were no observations that fell under this category that would be labelled as either Medium Risk or Low Risk. Regarding the observations, 900 or 50% of the practices were classified as Medium Risk. There were no such observations ranging from High Risk to Low Risk indicated in this category. Of them, 900 (50%) patients were assigned to the Low-Risk group. There were no Observation-based findings categorized under High Risk or Medium Risk in this Domain. These results suggest that equal or similar number of observations falls in the category of 'Medium Risk' and 'Low Risk' which is 50% respectively. There is about one-quarter, or 25%, of the total observations under the High-Risk category, thus depicting a still substantial but less in number as compared to the previous High-Risk group. Summing up, the distribution of observations exposes an equal ratio between the assessed risks according to the established Medium Risk and Low Risk levels and fewer numbers of observations assigned to the High-Risk classification. Depending on the established risk levels, it is possible to come up with specific risk management and intervention measures to be adopted.

Risk Stratification

Table 02: Example of Personalized Preventive Measures Based on Risk Categories

Risk Category	Recommended Actions
High Risk	Increased frequency of screenings, lifestyle modification advice, and genetic counseling.
Medium Risk	Regular screenings, periodic risk assessments, and moderate lifestyle adjustments.
Low Risk	General health maintenance advice and periodic health check-ups.

Model Validation

Figure No 03: Cross-Validation Results



The findings indicate what follows: The accuracy, precision, and recall of Model 1 are 0.82, 0.78, and 0 respectively. With an F1 score of 0.76, the classification has an accuracy of 80. After evaluation, the results showed that Model 2 had an accuracy of 0.81, precision of 0.79, recall of 0.79, and F1-score of 0.77. With an accuracy of 0.83, precision of 0.80, recall of 0.81, and F1-score of 0.78, Model 3 performed well. Inferentially, Model 4 displayed an F1-score of 0.77, accuracy of 0.82, precision of 0.79, and recall of 0. 80. DC accuracy of 0.84, precision of 0.81, and recall of 0 were displayed by Model 5, the Precision is 0.93, Recall is 0.82, and F1-score is 0.79. After analyzing the results of the five models, it was discovered that Model 5 performed the best, with an accuracy level of 0. 84, precision of 0. 81, recall of 0. in 82 documents, and F1-score of 0. 79. This suggests that Model 5 is the best model for text classification with the best precision-to-recall ratio, and hence has the highest F1 score. As for the Model 3 accuracy it was a hefty 0. 83, precision of 0. 80, recall of 0. Also, the overall accuracy of the study is revealed, 81, and the F1-score of 0. 78. Similarly to Model 5, the metrics of this model match the criterion well, so this is another viable candidate. So, for both the models 1 and 4, the accuracy obtained was 0. 82 with precision, recall and F1-score all scored 0.82, almost implying the same performance. Although these models were balanced in their performance, Models 3 and 5, provided slightly better results. It was observed that Model 2 had the least accuracy of 0. 81 though it succeeded in keeping precision & recall %, the F1 score was 0. 77. But the latter indicates that even this model, which turned out to be the lowest performing of all models in this set, can be considered a viable model. Conclusively, it has been observed that Model 5 performs the best out of all the models in terms of AM, AU, correlation, and time taken, this is followed by model 3. Similar to the performance of Model 1 and 4 in terms of accuracy, Model 2 is slightly lower, but still keeps with into the percentile.

Table 04: Performance of Ensemble Methods



It is important to mention the results of the Voting Classifier, which showed the accuracy of 0. 20 and a magnification at 0. 83, a recall of 0. 85, precision of 0.90, recall of 0.91, and an F1-score of 0. Overall accuracy, sensitivity = 86 %, specificity = 78 %, and the AUC-ROC value was 0. undefined the following metrics show that the Voting Classifier offers an optimistic precision rate and an appropriate recall rate, thereby creating a fair F1- score. The high overall performance is also confirmed by a high AUC-ROC value, which makes classification accurate. It can also be as observed from the results that the performance of Stacking Classifier was marginally better as per all the metrics than the Voting Classifier. It also did rather well in terms of accuracy, attaining approximately 0. 85, which attests to the high accuracy of the software with a precision of 0. Only seven of the cars were returned to the dealership with an average age of 84 months, a recall rate of 0. 86, an accuracy of 88%, a precision of 92%, a recall rate of 97%, an F1-score of 0. 85, making the model highly accurate in diagnosing the condition with an AUC-ROC of 0. undefined It is evident from the above results that the Stacking Classifier yields slightly better precision and recall to result in a higher F1-score and AUC-ROC as compared to the Voting Classifier. To sum up, it is evident that both Voting Classifier and Stacking Classifier are quite reliable. Even so, the Stacking Classifier fared better than its counterpart Voting Classifier for all the assessed indices, and thus remains the superior model in this comparison.

Results

The findings reveal that ML algorithms along with DL algorithms such as CNN attained the better results compared to other algorithms in terms of accuracy and AUC-ROC. Further based on the risk assessment results, it was identified that most of the patients fell under the medium to low-risk category, and thus appropriate prevention strategies were recommended. When the models were validated on the independent datasets, observations from the cross-validation experiments were supported, and thus the reality of the source and specificity of the models was once again underlined. Such studies provide a good example of how the use of machine learning contributes to the improvement of cancer risk models and individual prevention approaches. This implies that CNNs are more suited in high dimensional data, for instance, in genomic sequence data and imaging data. This improved performance complements the models' ability to increase the predictive and discriminative powers of the techniques. The above results of risk stratification show that using ML models, one can correctly determine the degree of risk and divide people into three categories high, middle, and low-risk ones. About quarter of the participants were identified as belonging to the high-risk category that requires more frequent examinations and targeted prevention programs. Such a stratification is helpful to prevent the diseases which can assist in reducing the cases of cancer incidences by at least providing a focus to work with depending on the predisposed risks of every individual. The rest of those examined were separated into groups of those with moderate and low risk; and, the preventive measures recommended to each group were also different. The need to apply ethical principles in the process of using the machine learning algorithms with reference to the objectives of preventing cancer cannot be overemphasized. Concerning patient information, privacy and proper consent are vital, especially concerning their health information. This phenomenon study complied with ethical standards since participants' information was concealed to avoid identification. However, the problem of introducing discrimination in the models must also be solved, making certain adjustments to achieve it. The study dealt effectively with biases by incorporating measures to avoid them for instances the study had to use representative samples.

Challenges and Limitations

A number of issues and pitfalls were realized during this study process. An example of the major challenge identified was the way in which the incoming data stemmed from genetic data, as well as data related to the environment and the users' life experience. But to have an excellent model, the quality and regularity of such sources need to be controlled to high standards. Also, the results showed that whereas the overall accuracy of the models using machine learning techniques was high, the models' interpretability was still an issue. Advanced mathematical tools like the deep learning models are sometimes hard to decode by clinicians for use in their fields. There is a need for more transparent modeling and valuable information to be incorporated in order to see wider application of these models within the clinical practice. The first is the use of pre-existing datasets which limits the range of choices of populations by researchers.

Future Directions

To ensure the applicability of the developed machine learning models, future studies should consider how the machine learning models interact with other advanced technologies like the wearable technology devices and real-time health monitoring systems. It also suggested that new developments could offer individualized and more constant analysis of dangers, which will improve the effectiveness of such interventions. Furthermore, the preemptive, continuing pursuit of better interpretability of artificial intelligence shall continue to be a crowning factor in its utilization in the clinical setting. Engaging data scientists, clinicians, and ethicists will also be important for tackling the ethical challenges raised by the integration of AI into the process of preventing cancer.

Conclusion

In conclusion, the application of the machine learning models has great potential in enhancing the cancer prevention efforts through the risk profiling and subsequent intervention. The results of the study show both the benefits of developing new strategies for cancer prevention with the help of AI and the possibilities of this technology in the future of healthcare. Mitigating the limitations that this study has outlined is paramount for the advancement of machine learning in cancer prevention and subsequent integration into practice. This study demonstrates the importance of machine learning in the prevention of cancer treatments. The analysis of accuracy, precision, recall, and AUC-ROC indicate that these models are useful to analyses complex data and recognize subtle patterns that could be overlooked when using conventional approaches Although the risk stratification outcomes show that machine learning can be employed to classify individuals into different risk groups in order to implement appropriate and specific preventive measures. Thus, by directing more attention and care to the high-risk group and offering recommendations to those with middle and low risk, reducing cancer risk and increasing the survival rate among patients is possible. But the study also looks at significant risks and limitations that arise, among which there is a demand for different and high-quality data sets, interpretability issues of complex models, and the problem of data privacy and data bias. It will be important to address these challenges for the effective application of machine learning models in the clinical practice. Further studies should attempt to combine these models with other innovative technologies which are soon to be adopted in the healthcare practice such as real-time health check and wearables. Furthermore, efforts aimed at enhancing model interpretability and at the integration of data scientists, clinicians, and ethicists will be crucial in addressing the existing challenges and in the conforming application of AI in healthcare. As a result, this study supports the future development and usage of Machine Learning in the fight against cancer. The potential in using these technologies to offer more reliable risk assessment and specific treatments is a way forward in improving public health and cancer treatment.

References:

1. Abbas, J., et al., Investment in renewable energy and electricity output: Role of green finance, environmental tax, and geopolitical risk: Empirical evidence from China. Energy, 2023. 269: p. 126683.
2. Afolabi LO, Afolabi MO, Sani MM, et al. Exploiting the CRISPR-Cas9 gene-editing system for human cancers and immunotherapy. *Clinical Translat Immunol*. 2021;10(6): e1286. doi: 10.1002/cti2.1286
3. Agarap AFM. On breast cancer detection: an application of machine learning algorithms on the Wisconsin diagnostic dataset. In: Proceedings of the 2nd international conference on machine learning and soft computing; 2018:5–9.
4. Agrawal S, Agrawal J. Neural network techniques for cancer prediction: a survey. *Procedia Comput Sci*. 2015; 60:769–774. doi: 10.1016/j.procs.2015.08.234
1. Ahmad M, Khan Z, Rahman ZU, Khattak SI, Khan ZU. Can innovation shocks determine CO2 emissions (CO2e) in the OECD economies? A new perspective. *Econ Innov New Technol*. 2021;**30**(1):89–109. doi: 10.1080/10438599.2019.1684643
5. Alawad M, Gao S, Shekar MC, et al. Integration of domain knowledge using medical knowledge graph deep learning for cancer phenotyping. *arXiv preprint arXiv*. 2021; 2021:210101337.
6. Aldabbas, M., et al. Future security challenges for smart societies: Overview from technical and societal perspectives. in 2020 International Conference on Smart Grid and Clean Energy Technologies (ICSGCE). 2020. IEEE.

7. Almond CS, Gauvreau K, Canter CE, Rajagopal SK, Piercey GE, Singh TP: A risk-prediction model for in-hospital mortality after heart transplantation in US children. Am J Transplant. 2012, 12:1240-8. 10.1111/j.1600-6143.2011.03932.x
8. Alpaydin E. *Introduction to Machine Learning*. MIT press; 2020.
9. Alvarez-Romero C, Martínez-García A, Sinaci AA, et al. FAIR4Health: findable, accessible, interoperable and reusable data to foster health research. *Open Res Eur*. 2022; 2:34. doi: 10.12688/openreseurope.14349.1
10. Anderson JP, Parikh JR, Shenfeld DK, et al. Willke RJ: reverse engineering and evaluation of prediction models for progression to type 2 diabetes: an application of machine learning using electronic health records. *J Diabetes Sci Technol*. 2016;**10**(1):6–18. doi: 10.1177/1932296815620200
11. Avanzo M, Stancanello J, Pirrone G, Sartor G. Radiomics and deep learning in lung cancer. *Strahlenther Onkol*. 2020;**196**(10):879–887. doi: 10.1007/s00066-020-01625-9
12. Baduge SK, Thilakarathna S, Perera JS, et al.: Artificial intelligence and smart vision for building and construction 4.0: Machine and deep learning methods and applications. Autom Constr. 2022, 141:104440. 10.1016/j.autcon.2022.104440
13. Bae S, An C, Ahn SS, et al. Robust performance of deep learning for distinguishing glioblastoma from single brain metastasis using radiomic features: model development and validation. *Sci Rep*. 2020;**10**(1):1–10. doi: 10.1038/s41598-020-68980-6
14. Bahado-Singh RO, Vishweswaraiah S, Aydas B, et al.: Precision cardiovascular medicine: artificial intelligence and epigenetics for the pathogenesis and prediction of coarctation in neonates. J Matern Fetal Neonatal Med. 2022, 35:457-64. 10.1080/14767058.2020.1722995
15. Baihakki MA, Qutayan SM: Ethical issues of artificial intelligence (AI) in the healthcare. J Sci Technol Innov Policy. 2023, 9:32-8. 10.11113/jostip.v9n1.129
16. Basu K, Sinha R, Ong A, Basu T. Artificial intelligence: how is it changing medical sciences and its future? *Indian J Dermatol*. 2020;**65**(5):365–370. doi: 10.4103/ijd.IJD_421_20
17. Batool, Aliza, Umar Farooq, Afshan Shafi, Zulqurnain Khan, Muhammad Ikram, Muhammad Shahbaz, Mariam Iqbal, Naqi Abbas, and Zahid Rafiq. "Chemo-Modulatory Potential of Flaxseed Oil as Natural Anticancer Therapeutic." *Advancements in Life Sciences* 10, no. 3 (2023): 362-367.
18. Bębas E, Borowska M, Derlatka M, et al. Machine-learning-based classification of the histological subtype of non-small-cell lung cancer using MRI texture analysis. *Biomed Signal Process Control*. 2021; 66:102446. doi: 10.1016/j.bspc.2021.102446
19. Bhinder B, Gilvary C, Madhukar NS, Elemento O. Artificial intelligence in cancer research and precision medicine. *Cancer Discov*. 2021;**11**(4):900–915. doi: 10.1158/2159-8290.CD-21-0090
20. Bibault J-E, Chang DT, Xing L. Development and validation of a model to predict survival in colorectal cancer using a gradient-boosted machine. *Gut*. 2021;**70**(5):884–889. doi: 10.1136/gutjnl-2020-321799
21. Bohr A, Memarzadeh K: The rise of artificial intelligence in healthcare applications. Artificial Intelligence in Healthcare. 2020, 25-60. 10.1016/B978-0-12-818438-7.00002-2
22. Breiman, L. (2001). Random forests. *Machine Learning*, 45(1), 5-32.
23. Cancer Genome Atlas Research Network. (2013). The Cancer Genome Atlas Pan-Cancer analysis project. *Nature Genetics*, 45(10), 1113-1120.
24. Cao J-S, Z-Y L, Chen M-Y, et al. Artificial intelligence in gastroenterology and hepatology: status and challenges. *World J Gastroenterol*. 2021;**27**(16):1664. doi: 10.3748/wjg. v27.i16.1664
25. Capper D, Stichel D, Sahm F, et al. Practical implementation of DNA methylation and copy-number-based CNS tumor diagnostics: The Heidelberg experience. *Acta Neuropathol*. 2018;**136**(2):181–210. doi: 10.1007/s00401-018-1879-y
26. Caruana, R., Gehrke, J., Koch, P., Nair, S., & Sturm, M. (2015). Intelligible models for healthcare: Predicting pneumonia risk and hospital 30-day readmission. *Proceedings of the 21th ACM SIGKDD International Conference on Knowledge Discovery and Data Mining*, 1721-1730.
27. CDC. (2021). National Health and Nutrition Examination Survey (NHANES). Retrieved from https://www.cdc.gov/nchs/nhanes/index.htm
28. Chang AC: Artificial intelligence in pediatric cardiology and cardiac surgery: Irrational hype or paradigm shift?. Ann Pediatr Cardiol. 2019, 12:191-4. 10.4103/apc.APC_55_19
29. Chang Junior J, Binuesa F, Caneo LF, et al.: Improving preoperative risk-of-death prediction in surgery congenital heart defects using artificial intelligence model: a pilot study. PLoS One. 2020, 15: e0238199. 10.1371/journal.pone.0238199
30. Cifarelli CP, Sheehan JP. Large language model artificial intelligence: the current state and future of ChatGPT in neuro-oncology publishing. *J Neurooncol*. 2023. doi: 10.1007/s11060-023-04336-0
31. Corral-Acero J, Margara F, Marciniak M, et al.: The 'Digital Twin' to enable the vision of precision cardiology. Eur Heart J. 2020, 41:4556-64. 10.1093/eurheartj/ehaa159
32. Cortes, C., & Vapnik, V. (1995). Support-vector networks. *Machine Learning*, 20(3), 273-297.
33. Danaee P, Ghaeini R, Hendrix DA: A deep learning approach for cancer detection and relevant gene identification. In: Pacific symposium on biocomputing 2017; World Scientific; 2017:219–229.
34. Dananjayan S, Raj GM. Artificial Intelligence during a pandemic: the COVID –19 example. *Int J Health Plann Manage*. 2020; 35:1260–1262. doi: 10.1002/hpm.2987

35. Dawes TJ, de Marvao A, Shi W, et al.: Machine learning of three-dimensional right ventricular motion enables outcome prediction in pulmonary hypertension: a cardiac MR imaging study. Radiology. 2017, 283:381-90. 10.1148/radiol.2016161315
36. Deschryver, P. and F. De Mariz, What future for the green bond market? How can policymakers, companies, and investors unlock the potential of the green bond market? Journal of Risk and Financial Management, 2020. 13(3): p. 61.
37. Diller GP, Kempny A, Babu-Narayan SV, et al.: Machine learning algorithms estimating prognosis and guiding therapy in adult congenital heart disease: data from a single tertiary center including 10 019 patients. Eur Heart J. 2019, 40:1069-77. 10.1093/eurheartj/ehy915
38. Diller GP, Orwat S, Vahle J, et al.: Prediction of prognosis in patients with tetralogy of Fallot based on deep learning imaging analysis. Heart. 2020, 106:1007-14. 10.1136/heartjnl-2019-315962
39. Dlamini Z, Francies FZ, Hull R, Marima R. Artificial intelligence (AI) and big data in cancer and precision oncology. *Comput Struct Biotechnol J*. 2020; **18:2300**–2311. doi: 10.1016/j.csbj.2020.08.019
40. Doolub G, Mamalakis M, Alabed S, et al.: Artificial intelligence as a diagnostic tool in non-invasive imaging in the assessment of coronary artery disease. Med Sci (Basel). 2023, 11:20. 10.3390/medsci11010020
41. Dreher C, Linde P, Boda-Heggemann J, Baessler B. Radiomics for liver tumours. *Strahlenther Onkol*. 2020;**196**(10):888–899. doi: 10.1007/s00066-020-01615-x [
42. Dwivedi AK. Artificial neural network model for effective cancer classification using microarray gene expression data. *Neural Comput Appl*. 2018;**29**(12):1545–1554. doi: 10.1007/s00521-016-2701-1
43. Enshaei A, Robson C, Edmondson R. Artificial intelligence systems as prognostic and predictive tools in ovarian cancer. *Ann Surg Oncol*. 2015;**22**(12):3970–3975. doi: 10.1245/s10434-015-4475-6
44. EPA. (2021). Environmental Protection Agency (EPA) Data. Retrieved from https://www.epa.gov
45. Ertel W. *Introduction to Artificial Intelligence*. Springer; 2018.
46. Esteva A, Kuprel B, Novoa RA, et al. Dermatologist-level classification of skin cancer with deep neural networks. *Nature*. 2017;**542**(7639):115–118. doi: 10.1038/nature21056 [
47. Esteva, A., Kuprel, B., Novoa, R. A., Ko, J., Swetter, S. M., & Blau, H. M. (2017). Dermatologist-level classification of skin cancer with deep neural networks. *Nature*, 542(7639), 115-118.
48. Farooq, R. et al., Do green human resource management and self-efficacy facilitate green creativity? A study of luxury hotels and resorts. Journal of Sustainable Tourism, 2022. 30(4): p. 824-845.
49. Feng H, Yang B, Wang J, et al. Identifying Malignant Breast Ultrasound Images Using ViT-Patch. *Appl Sci*. 2023;**13**(6):3489. doi: 10.3390/app13063489
50. Fletcher RR, Nakeshimana A, Olubeko O: Addressing fairness, bias, and appropriate use of artificial intelligence and machine learning in global health. Front Artif Intell. 2021, 3:561802. 10.3389/frai.2020.561802/full
51. Folorunso S, Ogundepo E, Basajja M, et al. FAIR machine learning model pipeline implementation of COVID-19 data. *Data Intelli*. 2022;**4**(4):971–990. doi: 10.1162/dint_a_00182
52. Forcier MB, Gallois H, Mullan S, Joly Y: Integrating artificial intelligence into health care through data access: can the GDPR act as a beacon for policymakers?. J Law Biosci. 2019, 6:317-35. 10.1093/jlb/lsz013
53. Friedman, J. H. (2001). Greedy function approximation: A gradient boosting machine. *Annals of Statistics*, 29(5), 1189-1232.
54. Gao Q, Zhu H, Dong L, et al. Integrated proteogenomic characterization of HBV-related hepatocellular carcinoma. *Cell*. 2019;**179**(2):561–577. e522. doi: 10.1016/j.cell.2019.08.052
55. Garcia-Canadilla P, Sanchez-Martinez S, Crispi F, Bijnens B: Machine learning in fetal cardiology: what to expect. Fetal Diagn Ther. 2020, 47:363-72. 10.1159/000505021
2. Gaur K, Jagtap MM. Role of artificial intelligence and machine learning in prediction, diagnosis, and prognosis of cancer. *Cureus*. 2022;**14**(11). doi: 10.7759/cureus.
56. Gay V, Leijdekkers P. Bringing health and fitness data together for connected health care: mobile apps as enablers of interoperability. *J Med Internet Res*. 2015;17(11):e260. doi: 10.2196/jmir.5094
57. Gerke S, Minssen T, Cohen G: Ethical and legal challenges of artificial intelligence-driven healthcare. Artif Intell Healthc. 2020, 295-336. 10.1016/B978-0-12-818438-7.00012-5
58. Ghassemi M, Naumann T, Schulam P, Beam AL, Chen IY, Ranganath R. Practical guidance on artificial intelligence for health-care data. *Lancet Digital Health*. 2019;**1**(4):e157–e159. doi: 10.1016/S2589-7500(19)30084-6 [PubMed]
59. Gogleva A, Polychronopoulos D, Pfeifer M, et al. Knowledge graph-based recommendation framework identifies drivers of resistance in EGFR mutant non-small cell lung cancer. *Nat Commun*. 2022;**13**(1):1667. doi: 10.1038/s41467-022-29292-7
60. Goldenberg SL, Nir G, Salcudean SE. A new era: artificial intelligence and machine learning in prostate cancer. *Nat Rev Urol*. 2019;**16**(7):391–403. doi: 10.1038/s41585-019-0193-3
61. Govindan, K., How artificial intelligence drives sustainable frugal innovation: A multitheoretical perspective. IEEE Transactions on Engineering Management, 2022.
62. Gul, Fahmida, Samreen Memon, Ikramuddin Ujjan, Pushpa Goswami, and Kanwal Abbas Bhatti. "The effects of 4β-hydroxy withanolide E extracted from Physalis Peruviana on Complete Blood Count of

Dimethylbenz (a) anthracene-induced Breast Cancer in Albino Rats." *Advancements in Life Sciences* 10, no. 3 (2023): 434-438.
63. Gupta MD, Kunal S, Girish MP, Gupta A, Yadav R: Artificial intelligence in cardiology: the past, present and future. Indian Heart J. 2022, 74:265-9. 10.1016/j.ihj.2022.07.004
64. Gupta S, Gupta M. Deep learning for brain tumor segmentation using magnetic resonance images. In: 2021 IEEE conference on computational intelligence in bioinformatics and computational biology (CIBCB); IEEE; 2021:1–6.
65. Gupta S, Gupta MK, Shabaz M, Sharma A. Deep learning techniques for cancer classification using microarray gene expression data. *Front Physiol*. 2022;2002:1.
66. Gupta S, Gupta MK. Computational prediction of cervical cancer diagnosis using ensemble-based classification algorithm. *Comput J*. 2022;**65**(6):1527–1539. doi: 10.1093/comjnl/bxaa198
67. Guyon I, Weston J, Barnhill S, Vapnik V. Gene selection for cancer classification using support vector machines. *Mach Learn*. 2002;**46**(1):389–422. doi: 10.1023/A:1012487302797
68. Han G, Jin T, Zhang L, et al.: Adoption of compound echocardiography under artificial intelligence algorithm in fetal congenial heart disease screening during gestation. Appl Bionics Biomech. 2022, 2022:6410103. 10.1155/2022/6410103
3. Harbeck N, Gnant M. Breast cancer. *Lancet*. 2017;389(10074):1134–1150. doi: 10.1016/S0140-6736(16)31891-8
69. Hart GR, Roffman DA, Decker R, Deng J. A multi-parameterized artificial neural network for lung cancer risk prediction. *PLoS One*. 2018;13(10):e0205264. doi: 10.1371/journal.pone.0205264
70. Hartigan, J. A., & Wong, M. A. (1979). Algorithm AS 136: A K-means clustering algorithm. *Applied Statistics*, 28(1), 100-108.
71. Hasan SMS, Rivera D, Wu XC, Durbin EB, Christian JB, Tourassi G. Knowledge graph-enabled cancer data analytics. *IEEE J Biomed Health Inform*. 2020;24(7):1952–1967. doi: 10.1109/JBHI.2020.2990797]
72. He J, Baxter SL, Xu J, Xu J, Zhou X, Zhang K: The practical implementation of artificial intelligence technologies in medicine. Nat Med. 2019, 25:30-6. 10.1038/s41591-018-0307-0
73. Helman SM, Herrup EA, Christopher AB, Al-Zaiti SS: The role of machine learning applications in diagnosing and assessing critical and non-critical CHD: a scoping review. Cardiol Young. 2021, 31:1770-80. 10.1017/S1047951121004212
74. Hoffman JI, Kaplan S: The incidence of congenital heart disease. J Am Coll Cardiol. 2002, 39:1890-900. 10.1016/S0735-1097(02)01886-7
75. Hollon TC, Pandian B, Adapa AR, et al. Near real-time intraoperative brain tumor diagnosis using stimulated Raman histology and deep neural networks. *Nat Med*. 2020;26(1):52–58. doi: 10.1038/s41591-019-0715-9
76. Hoodbhoy Z, Jiwani U, Sattar S, Salam R, Hasan B, Das JK: Diagnostic accuracy of machine learning models to identify congenital heart disease: a meta-analysis. Front Artif Intell. 2021, 4:708365. 10.3389/frai.2021.708365
77. Hu F, Shi X, Wang H, et al. Is health contagious? —Based on empirical evidence from China family panel studies' data. *Front Public Health*. 2021; 9:691746. doi: 10.3389/fpubh.2021.691746
78. Huang S, Yang J, Fong S, Zhao Q. Artificial intelligence in cancer diagnosis and prognosis: opportunities and challenges. *Cancer Lett*. 2020; 471:61–71. doi: 10.1016/j.canlet.2019.12.007
79. Iqbal MJ, Javed Z, Sadia H, et al. Clinical applications of artificial intelligence and machine learning in cancer diagnosis: looking into the future. *Cancer Cell Int*. 2021;21(1):1–11. doi: 10.1186/s12935-021-01981-1
80. Jahan S, Islam MD, Islam L, et al.: Automated invasive cervical cancer disease detection at early stage through suitable machine learning model. SN Appl Sci. 2021, 3:806. 10.1007/s42452-021-04786-z
81. Ji S, Pan S, Cambria E, Marttinen P, Philip SY. A survey on knowledge graphs: representation, acquisition, and applications. *IEEE Tran Neural Net Learn Sys*. 2021;33(2):494–514. doi: 10.1109/TNNLS.2021.3070843
82. Jiang, F., Jiang, Y., Zhi, H., Dong, Y., Li, H., Ma, S., ... & Wang, Y. (2017). Artificial intelligence in healthcare: past, present and future. *Stroke and Vascular Neurology*, 2(4), 230-243.
83. Jianzhu B, Shuang L, Pengfei M, Yi Z, Yanshu Z. Research on early warning mechanism and model of liver cancer rehabilitation based on CS-SVM. *J Healthc Eng*. 2021;2021. doi: 10.1155/2021/6658776
84. Johnson KW, Torres Soto J, Glicksberg BS, et al.: Artificial intelligence in cardiology. J Am Coll Cardiol. 2018, 71:2668-79. 10.1016/j.jacc.2018.03.521
85. Jone P-N, Gearhart A, Lei H, et al.: Artificial intelligence in congenital heart disease: current state and prospects. JACC Adv. 2022, 1:100153. 10.1016/j.jacadv.2022.100153
86. Jordan MI, Mitchell TM. Machine learning: trends, perspectives, and prospects. *Science*. 2015;349(6245):255–260. doi: 10.1126/science.aaa8415
87. Jovel J, Greiner R. An introduction to machine learning approaches for biomedical research. *Front Med*. 2021;2021:8.
88. Kalis B, Collier M, Fu R. 10 promising AI applications in health care. *Harv Bus Rev*. 2018; 2018:1.

89. Kampaktsis PN, Siouras A, Doulamis IP, et al.: Machine learning-based prediction of mortality after heart transplantation in adults with congenital heart disease: a UNOS database analysis. Clin Transplant. 2023, 37: e14845. 10.1111/ctr.14845
90. Karatzia L, Aung N, Aksentijevic D: Artificial intelligence in cardiology: hope for the future and power for the present. Front Cardiovasc Med. 2022, 9:
91. Khandekar, M. J., Cohen, D. S., & Tannenbaum, C. (2011). The effectiveness of preventive strategies in cancer. *Annual Review of Public Health*, 32, 95-109.
92. Kharya S, Dubey D, Soni S. Predictive machine learning techniques for breast cancer detection. *Int J Comput Sci Inf Technol*. 2013;4(6):1023–1028. [Google Scholar]
93. Kourou, K., Exarchos, T. P., Karamouzis, M. V., & Kafatos, M. C. (2015). Machine learning applications in cancer prognosis and prediction. *Computational and Structural Biotechnology Journal*, 13, 8-17.
94. Kubat M. *An Introduction to Machine Learning*. Springer; 2017.
95. Kulkarni, A.V., S. Joseph, and K.P. Patil, Artificial intelligence technology readiness for social sustainability and business ethics: Evidence from MSMEs in developing nations. International Journal of Information Management Data Insights, 2024. 4(2): p. 100250.
96. Kumar Y, Gupta S, Singla R. Hu Y-C: a systematic review of artificial intelligence techniques in cancer prediction and diagnosis. *Arch Comput Methods Eng*. 2021; 2021:1–28.
97. Kwilinski, A., O. Lyulyov, and T. Pimonenko, Unlocking sustainable value through digital transformation: An examination of ESG performance. Information, 2023. 14(8): p. 444.
98. LeCun, Y., Bengio, Y., & Hinton, G. (2015). Deep learning. *Nature*, 521(7553), 436-444.
99. Ledziński Ł, Grześk G: Artificial intelligence technologies in cardiology. J Cardiovasc Dev Dis. 2023, 10:10.3390/jcdd10050202
100. Li W, Zhang Y, Chen F. ChatGPT in colorectal surgery: a promising tool or a passing fad? *Ann Biomed Eng*. 2023. doi: 10.1007/s10439-023-03232-y
101. Lv Z, Yu Z, Xie S, Alamri A. Deep learning-based smart predictive evaluation for interactive multimedia-enabled smart healthcare. *ACM Trans Multimedia Comput Commun Appl*. 2022;18(1):1–20.
102. Majumder A, Sen D. Artificial intelligence in cancer diagnostics and therapy: current perspectives. *Indian J Cancer*. 2021;58(4):481. doi: 10.4103/ijc.IJC_399_20
103. Matsuo K, Machida H, Shoupe D, et al. Ovarian conservation and overall survival in young women with early-stage low-grade endometrial cancer. *Obstet Gynecol*. 2016;128(4):761. doi: 10.1097/AOG.0000000000001647
104. McKinney SM, Sieniek M, Godbole V, et al. International evaluation of an AI system for breast cancer screening. *Nature*. 2020;577(7788):89–94. doi: 10.1038/s41586-019-1799-6
105. Merriam G: If A.I. only had a heart: why artificial intelligence research needs to take emotions more seriously. J Artif Intell Conscious. 2022, 9:73-91. 10.1142/S2705078521500120
106. Miotto R, Li L, Kidd BA, Dudley JT. Deep patient: an unsupervised representation to predict the future of patients from the electronic health records. *Sci Rep*. 2016;6(1):1–10. doi: 10.1038/srep26094
107. Mohamed SK, Nounu A, Nováček V. Biological applications of knowledge graph embedding models. *Brief Bioinform*. 2021;22(2):1679–1693. doi: 10.1093/bib/bbaa012
108. Mori Y, Kudo SE. Detecting colorectal polyps via machine learning. *Nat Biomed Eng*. 2018;2(10):713–714. doi: 10.1038/s41551-018-0308-9
109. Muhammad W, Hart GR, Nartowt B, et al. Pancreatic cancer prediction through an artificial neural network. *Front Artif Intell*. 2019;2:2. doi: 10.3389/frai.2019.00002
110. Musa IH, Afolabi LO, Zamit I, et al. Artificial intelligence and machine learning in cancer research: a systematic and thematic analysis of the top 100 cited articles indexed in Scopus database. *Cancer Control*. 2022; 29:10732748221095946. doi: 10.1177/10732748221095946]
111. Nartowt BJ, Hart GR, Muhammad W, Liang Y, Stark GF, Deng J. Robust machine learning for colorectal cancer risk prediction and stratification. *Front Big Data*. 2020;3:6. doi: 10.3389/fdata.2020.00006
112. Nartowt BJ, Hart GR, Roffman DA, et al. Scoring colorectal cancer risk with an artificial neural network based on self-reportable personal health data. *PLoS One*. 2019;14(8):e0221421. doi: 10.1371/journal.pone.0221421
113. Naruka V, Arjomandi Rad A, Subbiah Ponniah H, et al.: Machine learning and artificial intelligence in cardiac transplantation: a systematic review. Artif Organs. 2022, 46:1741-53. 10.1111/aor.14334
114. Nawaz, H., Ali, M. A., Rai, S. I., & Maqsood, M. (2024). Comparative Analysis of Cloud based SDN and NFV in 5g Networks. The Asian Bulletin of Big Data Management, 4(1), Science-4.
115. Nawaz, H., Maqsood, M., Ghafoor, A. H., Ali, S., Maqsood, A., & Maqsood, A. (2024). Huawei Pakistan Providing Cloud Solutions for Banking Industry: A Data Driven Study. The Asian Bulletin of Big Data Management, 4(1), 89-107.
116. Nazir, M., Shakil, S. & Khurshid, K. Role of deep learning in brain tumor detection and classification (2015 to 2020): a review. Comput. Med. Imaging Graph 91, 101940 (2021).
117. Negrouk, A. & Lacombe, D. Does GDPR harm or benefit research participants? An EORTC point of view. Lancet Oncol. 19, 1278–1280 (2018).
118. Nie W, Bao Y, Zhao Y, Liu A. Long dialogue emotion detection based on commonsense knowledge graph guidance. *IEEE Trans Multimedia*. 2023;1–15. doi: 10.1109/TMM.2023.3267295

119. Nurmaini S, Partan RU, Bernolian N, et al.: Deep learning for improving the effectiveness of routine prenatal screening for major congenital heart diseases. J Clin Med. 2022, 11:10.3390/jcm11216454
120. Nurmaini S, Rachmatullah MN, Sapitri AI, et al.: Deep learning-based computer-aided fetal echocardiography: application to heart standard view segmentation for congenital heart defects detection. Sensors (Basel). 2021, 21:10.3390/s21238007
121. Obermeyer, Z., Powers, B., Vogeli, C., & Mullainathan, S. (2019). Dissecting racial bias in an algorithm used to manage the health of populations. *Science*, 366(6464), 447-453.
122. Pantanowitz L, Quiroga-Garza GM, Bien L, et al. An artificial intelligence algorithm for prostate cancer diagnosis in whole slide images of core needle biopsies: a blinded clinical validation and deployment study. *Lancet Digital Health*. 2020;2(8):e407–e416. doi: 10.1016/S2589-7500(20)30159-X
123. Pappas, A. C., Chang, Y., & Iorio, A. (2021). Data quality and bias in machine learning applications for healthcare. *Journal of Biomedical Informatics*, 114, 103650.
124. Pappas, A. C., Chang, Y., & Iorio, A. (2021). Data quality and bias in machine learning applications for healthcare. *Journal of Biomedical Informatics*, 114, 103650.
125. Paradise, J.F., The role of green digital finance in achieving sustainable development goals in China's Belt and Road initiative, in Green digital finance and sustainable development goals. 2022, Springer. p. 167-185.
126. Sanchez, D.O.M. Corporate social responsibility challenges and risks of industry 4.0 technologies: a review. in Smart SysTech 2019; European conference on smart objects, systems and technologies. 2019. VDE.
127. Senders JT, Staples P, Mehrtash A, et al. An online calculator for the prediction of survival in glioblastoma patients using classical statistics and machine learning. *Neurosurgery*. 2020;86(2):E184–E192. doi: 10.1093/neuros/nyz403
128. Sethi Y, Patel N, Kaka N, et al.: Artificial intelligence in pediatric cardiology: a scoping review. J Clin Med. 2022, 11:10.3390/jcm11237072
129. Shameer K, Johnson KW, Glicksberg BS, Dudley JT, Sengupta PP: Machine learning in cardiovascular medicine: are we there yet?. Heart. 2018, 104:1156-64. 10.1136/heartjnl-2017-311198
130. Sharifani K, Amini M: Machine learning and deep learning: a review of methods and applications. World Inform Technol Eng J. 2023, 10:3898-904.
131. Shaw J, Rudzicz F, Jamieson T, Goldfarb A. Artificial intelligence and the implementation challenge. *J Med Internet Res*. 2019;21(7):e13659. doi: 10.2196/13659
132. Shen F, Liu S, Wang Y, Wang L, Afzal N, Liu H: Leveraging collaborative filtering to accelerate rare disease diagnosis. AMIA Annu Symp Proc. 2017, 2017:1554-63.
133. Sher T, Sharp R, Wright RS: Algorithms and bioethics. Mayo Clin Proc. 2020, 95:843-4. 10.1016/j.mayocp.2020.03.020
134. Shickel, B., Tighe, P. J., Bihorac, A., & Rashidi, P. (2018). Deep EHR: A survey of recent advances in deep learning techniques for electronic health record (EHR) analysis. *IEEE Journal of Biomedical and Health Informatics*, 22(5), 1589-1604.
135. Shickel, B., Tighe, P. J., Bihorac, A., & Rashidi, P. (2018). Deep EHR: A survey of recent advances in deep learning techniques for electronic health record (EHR) analysis. *IEEE Journal of Biomedical and Health Informatics*, 22(5), 1589-1604.
136. Sidey-Gibbons JAM, Sidey-Gibbons CJ. Machine learning in medicine: a practical introduction. *BMC Med Res Methodol*. 2019;19(1):64. doi: 10.1186/s12874-019-0681-4
137. Sirovich, B. E., & Welch, H. G. (2003). The frequency of screening mammography and the diagnosis of advanced breast cancer. *New England Journal of Medicine*, 348(17), 1672-1680.
138. Sivashanker K, Duong T, Resnick A, Eappen S. Health care equity: from fragmentation to transformation. *NEJM Catal Innov Care Deliv*. 2020;15.
139. Stark GF, Hart GR, Nartowt BJ, Deng J. Predicting breast cancer risk using personal health data and machine learning models. *PLoS One*. 2019;14(12):e0226765. doi: 10.1371/journal.pone.0226765
140. Stokman FN, de Vries PH. *Structuring Knowledge in a Graph*. Rijksuniversiteit Groningen; 1986.
141. Sudan, F.K., Environmental, Social, and Governance Investment in Green Energy Projects in Southeast Asia: Potential, Drivers, and Policy Options. ENVIRONMENTAL, SOCIAL, AND GOVERNANCE INVESTMENT, 2020: p. 154.
4. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin*. 2021;**71**(3):209–249. doi: 10.3322/caac.21660
142. Tian Y, Xiao H, Yang Y, et al. Crosstalk between 5-methylcytosine and N6-methyladenosine machinery defines disease progression, therapeutic response and pharmacogenomic landscape in hepatocellular carcinoma. *Mol Cancer*. 2023;22(1):1–25. doi: 10.1186/s12943-022-01706-6
143. Topol, E. J. (2019). High-performance medicine: the convergence of human and artificial intelligence. *Nature Medicine*, 25(1), 44-56.
144. Tran NK, Albahra S, May L, et al. Evolving applications of artificial intelligence and machine learning in infectious diseases testing. *Clin Chem*. 2022;68(1):125–133. doi: 10.1093/clinchem/hvab239

145. Troisi J, Cavallo P, Richards S, et al.: Noninvasive screening for congenital heart defects using a serum metabolomics approach. Prenat Diagn. 2021, 41:743-53. 10.1002/pd.5893
146. Tumuluru P, Ravi B. GOA-based DBN: grasshopper optimization algorithm-based deep belief neural networks for cancer classification. *Int J Appl Eng Res*. 2017;12(24):14218–14231.
147. Ungureanu A, Marcu AS, Patru CL, et al.: Learning deep architectures for the interpretation of first-trimester fetal echocardiography (LIFE) - a study protocol for developing an automated intelligent decision support system for early fetal echocardiography. BMC Pregnancy Childbirth. 2023, 23:20. 10.1186/s12884-022-05204-x
148. Vaishya R, Javaid M, Khan IH, Haleem A. Artificial Intelligence (AI) applications for COVID-19 pandemic. *Diabetes Metab Syndr*. 2020;14(4):337–339. doi: 10.1016/j.dsx.2020.04.012
149. Van den Eynde J, Manlhiot C, Van De Bruaene A, Diller GP, Frangi AF, Budts W, Kutty S: Medicine-based evidence in congenital heart disease: how artificial intelligence can guide treatment decisions for individual patients. Front Cardiovasc Med. 2021, 8:798215. 10.3389/fcvm.2021.798215
150. Wang H, Zu Q, Chen J, Yang Z, Ahmed MA. Application of artificial intelligence in acute coronary syndrome: a brief literature review. *Adv Ther*. 2021;38(10):5078–5086. doi: 10.1007/s12325-021-01908-2
151. Wang K-W, Dong M. Potential applications of artificial intelligence in colorectal polyps and cancer: recent advances and prospects. *World J Gastroenterol*. 2020;26(34):5090. doi: 10.3748/wjg. v26.i34.5090
152. Wang Z, Zhang J, Feng J, Chen Z. Knowledge graph embedding by translating on hyperplanes. In: Proceedings of the AAAI conference on artificial intelligence; 2014.
153. Wilkinson MD, Dumontier M, Aalbersberg IJ, et al. The FAIR Guiding Principles for scientific data management and stewardship. *Sci Data*. 2016;3(1):160018. doi: 10.1038/sdata.2016.18
154. World Health Organization. (2021). Cancer. Retrieved from https://www.who.int/news-room/fact-sheets/detail/cancer
5. World Health Organization. © International Agency for Research on Cancer, 2020. Cancer Today. Available from:https://gco.iarc.fr/today/online-analysis-pie?v=2020&mode=cancer&mode_population=continents&population=900&populations=900&key=total&sex=0&cancer=39&type=0&statistic=5&prevalence=0&population_group=0&ages_group%5B%5D=0&ages_group%5B%5D=17&nb_items=7&group_cancer=1&include_nmsc=1&include_nmsc_other=1&half_pie=0&donut=0. Accessed June 20, 2023.
155. Wrzeszczynski KO, Frank MO, Koyama T, et al. Comparing sequencing assays and human-machine analyses in actionable genomics for glioblastoma. *Neurol Genet*. 2017;3(4):e164. doi: 10.1212/NXG.0000000000000164 [PMC free article] [PubMed]
156. Yang DH: Application of artificial intelligence to cardiovascular computed tomography. Korean J Radiol. 2021, 22:1597-608. 10.3348/kjr.2020.1314
157. Yang S, Li Q, Li W, Li X, Liu -A-A. Dual-level representation enhancement on characteristic and context for image-text retrieval. *IEEE Trans Circuits Syst Video Technol*. 2022;32(11):8037–8050. doi: 10.1109/TCSVT.2022.3182426
158. Yu C, Helwig EJ. The role of AI technology in prediction, diagnosis and treatment of colorectal cancer. *Artif Intell Rev*. 2022;55(1):323–343. doi: 10.1007/s10462-021-10034-y
159. Zamini M, Reza H, Rabiei M. A review of knowledge graph completion. *Information*. 2022;13(8):396. doi: 10.3390/info13080396
160. Zeng X, Tu X, Liu Y, Fu X, Su Y. Toward better drug discovery with knowledge graph. *Curr Opin Struct Biol*. 2022; 72:114–126. doi: 10.1016/j.sbi.2021.09.003
161. Zhang P, Schmidt DC, White J, Lenz G. Chapter One - Blockchain Technology Use Cases in Healthcare. In: Raj P, Deka GC, editors. *Advances in Computers*. Vol. 111. Elsevier; 2018:1–41.
162. Zhao H, Ming T, Tang S, et al. Wnt signaling in colorectal cancer: pathogenic role and therapeutic target. *Mol Cancer*. 2022;21(1):144. doi: 10.1186/s12943-022-01616-7
163. Zhou, Z.-H. (2012). Ensemble Methods: Foundations and Algorithms. *CRC Press*.
164. Zhu, X., Xu, J., & Chen, H. (2020). Integrating genetic data and machine learning for improved colorectal cancer risk prediction. *Bioinformatics*, 36(5), 1501-1507.
165. Zhu, X., Xu, J., & Chen, H. (2020). Integrating genetic data and machine learning for improved colorectal cancer risk prediction. *Bioinformatics*, 36(5), 1501-1507. WHO. (2022). World Health Organization (WHO) Data. Retrieved from https://www.who.int/news-room/fact-sheets